Literature DB >> 22045472

VEGF gene alternative splicing: pro- and anti-angiogenic isoforms in cancer.

P M Biselli-Chicote1, A R C P Oliveira, E C Pavarino, E M Goloni-Bertollo.   

Abstract

Tumor growth and progression depend on angiogenesis, a process of new blood vessels formation from a preexisting vascular endothelium. Tumors promote angiogenesis by secreting or activating angiogenic factors that stimulate endothelial proliferation and migration and capillary morphogenesis. The newly formed blood vessels provide nutrients and oxygen to the tumor, increasing its growth. Thus, angiogenesis plays a key role in cancer progression and development of metastases. An important growth factor that promotes angiogenesis and participates in a variety of physiological and pathological processes is the vascular endothelial growth factor (VEGF-A or VEGF). Overexpression of VEGF results in increased angiogenesis in normal and pathological conditions. The existence of an alternative site of splicing at the 3' untranslated region of the mRNA results in the expression of isoforms with a C-terminal region which are downregulated in tumors and may have differential inhibitory effects. This suggests that control of splicing can be an important regulatory mechanism of angiogenesis in cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22045472     DOI: 10.1007/s00432-011-1073-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  61 in total

Review 1.  SR proteins and splicing control.

Authors:  J L Manley; R Tacke
Journal:  Genes Dev       Date:  1996-07-01       Impact factor: 11.361

2.  The protein kinase Clk/Sty directly modulates SR protein activity: both hyper- and hypophosphorylation inhibit splicing.

Authors:  J Prasad; K Colwill; T Pawson; J L Manley
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

Review 3.  Clinical implications of circulating angiogenic factors in cancer patients.

Authors:  R T Poon; S T Fan; J Wong
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

4.  A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2.

Authors:  S Cébe Suarez; M Pieren; L Cariolato; S Arn; U Hoffmann; A Bogucki; C Manlius; J Wood; K Ballmer-Hofer
Journal:  Cell Mol Life Sci       Date:  2006-09       Impact factor: 9.261

5.  VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.

Authors:  Jeanette Woolard; Wen-Ying Wang; Heather S Bevan; Yan Qiu; Lucia Morbidelli; Rowan O Pritchard-Jones; Tai-Gen Cui; Marto Sugiono; Elizabeth Waine; Rachel Perrin; Rebecca Foster; Jonathon Digby-Bell; Jacqueline D Shields; Cheryl E Whittles; Rosey E Mushens; David A Gillatt; Marina Ziche; Steven J Harper; David O Bates
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

6.  Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis.

Authors:  M Kaya; T Wada; T Akatsuka; S Kawaguchi; S Nagoya; M Shindoh; F Higashino; F Mezawa; F Okada; S Ishii
Journal:  Clin Cancer Res       Date:  2000-02       Impact factor: 12.531

7.  Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor.

Authors:  H M Fraser; S E Dickson; S F Lunn; C Wulff; K D Morris; V A Carroll; R Bicknell
Journal:  Endocrinology       Date:  2000-03       Impact factor: 4.736

Review 8.  Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.

Authors:  Napoleone Ferrara
Journal:  Semin Oncol       Date:  2002-12       Impact factor: 4.929

9.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

Review 10.  VEGF-A splicing: the key to anti-angiogenic therapeutics?

Authors:  Steven J Harper; David O Bates
Journal:  Nat Rev Cancer       Date:  2008-10-16       Impact factor: 60.716

View more
  35 in total

Review 1.  Methodologies in creating skin substitutes.

Authors:  Mathew N Nicholas; Marc G Jeschke; Saeid Amini-Nik
Journal:  Cell Mol Life Sci       Date:  2016-05-06       Impact factor: 9.261

2.  VEGFA isoforms play a vital role in oral cancer progression.

Authors:  Kinjal R Patel; Bhairavi N Vajaria; Rasheedunnisa Begum; Jayendra B Patel; Franky D Shah; Geeta M Joshi; Prabhudas S Patel
Journal:  Tumour Biol       Date:  2015-03-25

3.  Transcriptomic and Functional Evidence for Differential Effects of MCF-7 Breast Cancer Cell-Secretome on Vascular and Lymphatic Endothelial Cell Growth.

Authors:  Giovanna Azzarito; Michele Visentin; Brigitte Leeners; Raghvendra K Dubey
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

Review 4.  Tumor stroma as targets for cancer therapy.

Authors:  Jing Zhang; Jinsong Liu
Journal:  Pharmacol Ther       Date:  2012-10-12       Impact factor: 12.310

Review 5.  Folate-conjugated gold nanoparticle as a new nanoplatform for targeted cancer therapy.

Authors:  Hadi Samadian; Samira Hosseini-Nami; Seyed Kamran Kamrava; Habib Ghaznavi; Ali Shakeri-Zadeh
Journal:  J Cancer Res Clin Oncol       Date:  2016-05-21       Impact factor: 4.553

6.  MiR-9 regulates the post-transcriptional level of VEGF165a by targeting SRPK-1 in ARPE-19 cells.

Authors:  Changshin Yoon; Daejin Kim; Seonghan Kim; Ga Bin Park; Dae Young Hur; Jae Wook Yang; Sae Gwang Park; Yeong Seok Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-10       Impact factor: 3.117

Review 7.  Alternative RNA splicing and cancer.

Authors:  Sali Liu; Chonghui Cheng
Journal:  Wiley Interdiscip Rev RNA       Date:  2013-06-13       Impact factor: 9.957

Review 8.  Misregulation of pre-mRNA alternative splicing in cancer.

Authors:  Jian Zhang; James L Manley
Journal:  Cancer Discov       Date:  2013-10-21       Impact factor: 39.397

9.  Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death.

Authors:  Kashif Rafiq Zahid; Shiming Han; Fuling Zhou; Umar Raza
Journal:  Cell Oncol (Dordr)       Date:  2018-09-20       Impact factor: 7.051

Review 10.  The role of the cell-cell interactions in cancer progression.

Authors:  Katarzyna Kamińska; Cezary Szczylik; Zofia F Bielecka; Ewa Bartnik; Camillo Porta; Fei Lian; Anna M Czarnecka
Journal:  J Cell Mol Med       Date:  2015-01-19       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.